Can Shorter TB Prevention Regimens Work?
Randomized study evaluates efficacy, safety, and completion in high-risk patients
By
Julia Cipriano, MS, CMPP
March 23, 2026
Clinical Scorecard: Can Shorter TB Prevention Regimens Work?
At a Glance
Category Detail
Condition Tuberculosis (TB) prevention in patients with rheumatic diseases Key Mechanisms Modified 3-month rifapentine plus isoniazid regimen Target Population Patients aged 18 to 70 years with high-risk rheumatic diseases and latent TB infection Care Setting Tertiary general hospitals
Key Highlights
3-month rifapentine plus isoniazid (3HP) regimen showed noninferiority to standard 9-month isoniazid (9H) regimen Cumulative TB rate was 0% in 3HP group vs 1.2% in 9H group Adverse drug reactions were lower in 3HP group (9.6%) compared to 9H group (15%) Treatment completion rates were similar: 89.6% for 3HP vs 91.2% for 9H Study provides high-level evidence for a viable alternative TB prevention regimen Guideline-Based Recommendations
Diagnosis
Consider screening for latent TB in patients with rheumatic diseases on immunosuppressive therapy Management
Consider 3-month rifapentine plus isoniazid regimen as an alternative to the standard 9-month regimen Monitoring & Follow-up
Monitor for adverse drug reactions and hepatotoxicity during treatment Risks
Potential for lower event rates and limited generalizability beyond high-risk populations Patient & Prescribing Data
Patients with rheumatic diseases receiving immunosuppressive therapy
Short-course regimens may reduce treatment burden and drug toxicity
Clinical Best Practices
Encourage treatment adherence through patient education on the benefits of shorter regimens Evaluate patient comorbidities and concomitant medications before prescribing Consider the impact of the COVID-19 pandemic on TB exposure and reporting Related Resources & Content
